Advances in anticoagulation management: The role of pharmacy

Annals of Pharmacotherapy

Volumn 41, Issue 3, 2007, Pages 493-495

  Smythe, Maureen A ^a,b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; COUMARIN; FONDAPARINUX; HEPARIN; HIRUDIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; BLEEDING; CLINICAL PRACTICE; CLINICAL PROTOCOL; COST BENEFIT ANALYSIS; DRUG SAFETY; HEALTH CARE SYSTEM; HEMOPHILIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; NOMOGRAM; OFF LABEL DRUG USE; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PHARMACIST; PHARMACY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; THROMBOCYTE COUNT; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HEPARIN; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PHARMACISTS; PROFESSIONAL ROLE; THROMBIN; THROMBOEMBOLISM; WARFARIN;

EID: 34047198648     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K035     Document Type: Short Survey

References (10)

1. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998;122:782-98.
2. Shahangian S, Stankovic AK, Lubin IM, et al. Results of a survey of hospital coagulation laboratories in the United States, 2001. Arch Pathol Lab Med 2005;129:47-60.
3. Favaloro EJ, Bonar R, Sioufi J, et al. An international survey of current practice in the laboratory assessment of anticoagulation therapy with heparin. Pathology 2005;37:234-8.
4. Rosborough TK, Shepard MF. Achieving target antifactor Xa activity with a heparin protocol based on sex, age, height and weight. Pharmacotherapy 2004;24:713-9.
5. Smythe MA, Koerber JL, Mattson JC. The heparin anti-Xa therapeutic range, are we there yet? Chest 2002;121:303-4.
6. Kearon C, Ginsberg JS, Julian JA, et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006; 296:935-42.
7. Gray DR, Garabedian-Ruffalo SM, Chretien SD. Cost-justification of a clinical pharmacist-managed anticoagulation clinic. Drug Intell Clin Pharm 1985;19:575-80.
8. Bond CA, Raehl CL. Pharmacist provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications and transfusions. Pharmacotherapy 2004;24: 953-63.
9. Joint Commission. National Consensus Standards for Prevention and Care of Venous Thromboembolism (VTE). www.jointcommission.org/ PerformanceMeasurement/ PerformanceMeasurement/National+Consensus +Standards+for+Prevention+and+Care+(VTE).htm (accessed 2007 Jan 25).
10. Dalen JE, Hirsh J, eds. ACCP-NHLBI National Conference on Antithrombotic Therapy. Chest 1986;89(suppl):1s-106s.